Oncotalks | Powered by Novartis

ASCO 2019 Dr. Susan Dent

ASCO , Latvia , Lithuania , Estonia , Albania , Slovenia
Share this item

Dr. Susan Dent from the Duke Cancer Institute, North Carolina, VS is commenting on Reference: DeLaurentiis M. et al. Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC). J Clin Oncol 37, 2019 (suppl; abstr 1041)

Related items

ASCO 2019 Prof. Axel Hauschild, MD

ASCO 2019 Prof. Axel Hauschild, MD

Prof. Axel Hauschild, MD from the University Hospital Schleswig-Holstein, Kiel is discussing "Nathan P.D. et al. Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. J Clin Oncol 37, 2019 (suppl; abstr 9507)", which was presented at ASCO 2019 in Chicago

ASCO , Lithuania , Hungary , Albania

00:03:36

ASCO 2019 Prof. Piotr Rutkowski, MD, PhD

ASCO 2019 Prof. Piotr Rutkowski, MD, PhD

Prof. Piotr Rutkowski, MD, PhD from the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw is commenting on the abstract: "Nathan P.D. et al. Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. J Clin Oncol 37, 2019 (suppl; abstr 9507", which was presented at ASCO 2019 in Chicago

ASCO , Lithuania , Hungary , Albania

00:06:31

ASCO 2019 Prof. Michelino DeLaurentiis, MD, PhD

ASCO 2019 Prof. Michelino DeLaurentiis, MD, PhD

Prof. Michelino DeLaurentiis, MD, PhD from the National Cancer Institute Fondazione G. Pascale is commenting on his abstract "DeLaurentiis M. et al. Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC). J Clin Oncol 37, 2019 (suppl; abstr 1041)", which was presented at ASCO 2019 in Chicago

ASCO , Kisqali Channel , Lithuania , Albania , Slovenia

00:03:07

ASCO 2019 Juan Martin-Liberal, MD, PhD

ASCO 2019 Juan Martin-Liberal, MD, PhD

Juan Martin-Liberal, MD, PhD from Institut Català d'Oncologia, BarcelonaCommenting on: Schadendorf D. et al. Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO). J Clin Oncol 37, 2019 (suppl; abstr 9582), presented at the ASCO 2019 in Chicago

ASCO , Lithuania , Albania

00:02:06

ASCO 2019 dr. Christos Sotiriou

ASCO 2019 dr. Christos Sotiriou

dr. Christos Sotiriou from the Jules Bordet Institute, Brussel is sharing his personal highlights from ASCO 2019 in ChicagoGenomic iterations that characterize de novo Stage 4 breast cancerThe use of potential biomarkers to that are specifically response immunotherapy in breast cancer.A proteomics to false reporting that also may predict response to mTOR inhibitors

ASCO , Lithuania , Albania

00:11:36

ASCO 2019 Ana Arance, MD, PhD

ASCO 2019 Ana Arance, MD, PhD

Ana Arance, MD, PhD from the Hospital Clínic de Barcelona is commenting on Nathan P.D. et al. Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. J Clin Oncol 37, 2019 (suppl; abstr 9507), which was presented at ASCO 2019 in Chicago

ASCO , Lithuania , Hungary , Albania

00:02:14